Diadexus Inc (DDXS) 0.3400 $DDXS
Diadexus, Inc. Names William Hammond as Vice President of Sales
Marketwired - Tue Jul 07, 8:15AM CDT
Diadexus, Inc. (OTCQB: DDXS), a diagnostics company developing and commercializing products that aid in the prediction of cardiac disease risk, today announced that William Harrison Hammond (Hodi) has joined the Company as Vice President of Sales effective June 22, 2015. Mr. Hammond brings more than 30 years of experience in the medical diagnostics field, including 13 years in various senior and executive roles at Alere and 11 years at Abbott Diagnostics.
Diadexus approves one for 15 reverse stock split
M2 - Thu Jul 02, 6:49AM CDT
Diagnostics company Diadexus (OTCQB
DXS) reported on Wednesday the completion of a one for-15 reverse stock split of its common stock on 30 June 2015.
Diadexus 1:15 reverse split shares trade today
Seeking Alpha - at Seeking Alpha - Wed Jul 01, 9:33AM CDT
Diadexus, Inc. Announces Reverse Stock Split
Marketwired - Wed Jul 01, 8:15AM CDT
Diadexus, Inc. (OTCQB: DDXS), a diagnostics company developing and commercializing products that aid in the prediction of cardiac disease risk, today announced that it has completed a 1-for-15 reverse stock split of its common stock, effective as of 5:00 pm Eastern Time June 30, 2015. Beginning with the opening of trading today the Company's common stock will trade on OTCQB on a post-split basis.
2015 UK Infectious Disease Molecular Diagnostics Market: Country Forecasts, Supplier Shares, Emerging Technologies and Competitive Landscape
M2 - Wed Jun 24, 6:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9b6wsz/2015_uk) has announced the addition of the "2015 UK Infectious Disease Molecular Diagnostics Market: Country Forecasts, Supplier Shares, Emerging Technologies and Competitive Landscape" report to their offering. This new study contains 977 pages, 50 tables, and is designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities in the infectious disease molecular diagnostics market during the next five years. In order to successfully capitalize on the opportunities presented by the infectious disease molecular diagnostics market, many companies are already exploiting new molecular technologies as corporate strategic assets, managed in support of business and marketing strategies. Integrating new technology planning with business and corporate strategies will be one of the most challenging tasks for diagnostic companies during the next five years. Report Highlights - Business and technological trends in major markets - Five-year test volume and sales forecasts - Market shares of leading competitors - Feature comparison of major analyzers - Strategic profiles of leading market players and start-up firms developing innovative products - Specific product and business opportunities for instrument and consumable suppliers. U.K. Market Overview - Laboratories performing DNA sequencing and molecular diagnostic testing for infectious diseases and market segment. - Five-year test volume and sales projections. Market Segmentation Analysis - Sales and market shares of leading suppliers of infectious disease molecular diagnostic reagent kits and components. - Five-year test volume and sales projections for over 40 infectious disease molecular diagnostic assays. - A comprehensive analysis of the sequencing market and laboratory segment. - Detailed market segmentation analysis, including review of the market dynamics, trends, structure, size, growth and major suppliers. Product/Technology Review - Comparison of leading infectious disease molecular diagnostic analyzers. - Extensive review of molecular diagnostic technologies, test formats, detection methodologies, trends in testing automation and over target/signal amplification methods. - Worldwide listings of companies, universities and research centers developing new molecular diagnostic technologies and products. Competitive Assessments - Abbott - Affymetrix - Agilent Technologies - Applied Gene Technologies - Arca Biopharma - Beckman Coulter/Danaher - Becton Dickinson - Biokit - bioMerieux - Bio-Rad - Biotest - Cepheid - CellMark Forenciscs/LabCorp - Decode Genetics - Diadexus - Hologic/Gen-Probe - Illumina - Kreatech - Li-Cor Biosciences - Monogram Biosciences/LabCorp - Myriad Genetics - Ortho-Clinical Diagnostics - Perkin Elmer/Caliper - Proteome Sciences - Qiagen - Roche - Scienion - Sequenom - Shimadzu - Siemens - Sierra Molecular - Takara Bio - Tecan Group - Thermo Fisher For more information visit http://www.researchandmarkets.com/research/9b6wsz/2015_uk
SQNM: 2.95 (+0.11), MYGN: 34.32 (+0.82), A: 39.40 (+0.48), CPHD: 58.15 (+0.75), DHR: 86.65 (+0.91), HOLX: 38.71 (+0.75)
2015 Cancer Diagnostics: A Market on the Verge of Explosion--Technological Breakthroughs, Emerging Tests, Market Forecasts, Competitive Intelligence
M2 - Thu Jun 18, 12:14PM CDT
Research and Markets (http://www.researchandmarkets.com/research/x472n5/2015_cancer) has announced the addition of the "2015 Cancer Diagnostics: A Market on the Verge of Explosion--Technological Breakthroughs, Emerging Tests, Market Forecasts, Competitive Intelligence" report to their offering. The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease.During the next five years, the worldwide cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field.Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy.The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide. Geographic Coverage France, Germany, Italy, Japan, Spain, UK, USA - The companies analyzed in the report include - Abbott - AdnaGen - Agilent Technologies - Applied Gene Technologies - Arca Pharma - Beckman Coulter/Danaher - Becton Dickinson - Biomedical Diagnostics - bioMerieux - Bio-Rad - CellSearch - Cepheid - Correlogic Systems/Vermillion - Decode Genetics - Diadexus - Diagnocure - Diasorin - Eiken Chemical - Elitech Group - Epigenomics - Enterix - Enzo Biochem - Exact Sciences - Fujirebio - Guided Therapeutics - Hologic/Gen-Probe - Kreatech/Leica - Kyowa Medex - Mackay Life Sciences - Myriad Genetics - OncoLab - Ortho-Clinical Diagnostics - Panacea Pharmaceuticals - Polartechnics - Polymedco - PreMD - Qiagen/Ipsogen - Quest Diagnostics - Radient Pharmaceuticals - Roche - Scienion - Sequenom - Siemens Healthcare - Takara Bio - Targeted Diagnostics & Therapeutics - Thermo Fisher - Tosoh - Veridex - Wako Pure Chemicals - Wallac/PE - Zila For more information visit http://www.researchandmarkets.com/research/x4...015_cancer About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
MYGN: 34.32 (+0.82), A: 39.40 (+0.48), DHR: 86.65 (+0.91), SQNM: 2.95 (+0.11), ENZ: 3.00 (+0.04), DGX: 71.58 (+0.74), CPHD: 58.15 (+0.75), HOLX: 38.71 (+0.75)
2015 New Frontiers in the Italian Cancer Diagnostics Market: Business Challenges, Emerging Technologies, Competitive Landscape (Datapack)
M2 - Wed Jun 10, 9:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/t5ptkf/2015_new) has announced the addition of the "2015 New Frontiers in the Italian Cancer Diagnostics Market: Business Challenges, Emerging Technologies, Competitive Landscape (Datapack)" report to their offering. This is a new study of the major business opportunities emerging in the Italian cancer diagnostics market during the next five years. The report examines trends in the Italian cancer diagnostics markets, reviews current and emerging assays; analyzes potential applications of new diagnostic technologies; forecasts sales of major tumor markers by market segment; profiles leading players and potential market entrants; and identifies specific business opportunities for suppliers. Italian Market Overview: - Five-year test volume and sales projections. - Comprehensive market segmentation analysis, including review of the market dynamics, structure, size, growth and major suppliers. - Estimated universe of laboratories performing cancer diagnostic testing. - Cancer statistics, etiology and recent developments. Business Opportunities and Strategic Recommendations: - Specific new product development opportunities with potentially significant market appeal during the next five years. - Design criteria for new products. - Alternative market penetration strategies. - Potential market entry barriers and risks. Over 200 Current and Emerging Cancer Diagnostic Test: - Biochemical Markers - Oncogenes - Growth Factors - Hormones - Colony Stimulating Factors - Lymphokines - Immunohistochemical Stains, and others. Supplier Shares, Sales and Volume Forecasts: - Sales and market shares of major cancer diagnostic product suppliers by individual test. - Five-year test volume and sales forecasts for major tumor markers by market segment, including: - Hospitals - Commercial/Private Laboratories Instrumentation Review: - Analysis of major molecular diagnostic and immunodignostic analyzers used for cancer testing, including their operating characteristics, features and selling prices. Technology Assessment: - Assessment of latest molecular diagnostic methods, biochips/microarrays, biosensors, monoclonal antibodies, immunoassays, chromosome analysis, IT, artificial intelligence, flow cytometry, and other technologies and their potential applications for cancer diagnostic testing. - Review of competing/complementing technologies, including CT, MRI, NMR, PET and photonics spectroscopy. - Extensive listings of companies, universities and research centers developing new cancer diagnostic tests and detection technologies. Competitive Strategies: - Strategic assessments of major suppliers and start-up firms developing innovative technologies and products, including their sales, product portfolios, marketing tactics, collaborative arrangements, and new products in R&D. Companies Mentioned - Abbott - AdnaGen/Alere - Agilent Technologies - Applied Gene Technologies - Arca Pharma - Bckman Coulter/Danaher - Becton Dickinson - Biomedical Diagnostics - bioMerieux - Bio-Rad - CellSearch - Cepheid - Correlogic Systems/Vermillion - Decode Genetics - Diadexus - Diagnocure - Enzo Biochem - Exact Sciences - Fujirebio - Guided Therapeutics - Hologic/Gen-Probe - Kreatech/Leica - Kyowa Medex - Mackay Life Sciences - Polymedco - PreMD - Qiagen - Quest Diagnostics - Radient Pharmaceuticals - Roche - Scienion - Sequenom - Wako Pure Chemicals - Wallac/PE - Zilla For more information visit http://www.researchandmarkets.com/research/t5ptkf/2015_new
SQNM: 2.95 (+0.11), ENZ: 3.00 (+0.04), A: 39.40 (+0.48), DGX: 71.58 (+0.74), CPHD: 58.15 (+0.75), HOLX: 38.71 (+0.75)
2015 Strategies in the US Physician Office and Group Practice Diagnostic Testing Market
M2 - Wed Jun 03, 10:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mqms5f/2015_strategies) has announced the addition of the "2015 Strategies in the US Physician Office and Group Practice Diagnostic Testing Market" report to their offering. This new 970-page report contains 152 tables and provides comprehensive analysis of the physician office/group practice diagnostics market, including its dynamics, size, growth, regulatory requirements, technological trends, competitive landscape, and emerging opportunities for instrument and consumable suppliers. Companies Mentioned: - Abbott - ADI/America Diagnostica - Agilent Technologies - Axis-Shield - Beckman Coulter/Danaher - Becton Dickinson - Bio/Data - Biomerieux - Bio-Rad - Biosite/Inverness/Alere - Cepheid - Chrono-Log - Corgenix - Decode - Diadexus - Diagnocure - Diagnostica Stago/Trinity Biotech - Diamedix - Diasorin - Eiken Chemical - EKF Diagnostics - Fujirebio/Innogenetics - Helena Laboratories - Hologic/Gen-Probe - Horiba - Instrumentation Laboratory - International Technidyne/Nexus DX - Kreatech - Kyowa Medex - Life Technologies - Lonza - Polymedco - Qiagen - Roche - SDIX For more information visit http://www.researchandmarkets.com/research/mq...strategies
LIFE: 18.36 (+3.03), A: 39.40 (+0.48), CPHD: 58.15 (+0.75), DHR: 86.65 (+0.91), HOLX: 38.71 (+0.75)
2015 Strategies in the Global Tumor Marker Testing Market
M2 - Fri May 29, 5:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kj6pzz/2015_strategies) has announced the addition of the "2015 Strategies in the Global Tumor Marker Testing Market: US, Europe, Japan" report to their offering. Identifies and evaluates major business opportunities emerging in the tumor marker market during the next five yearsExamines trends in the U.S., Europe and JapanReviews current and emerging tumor markersAnalyzes applications of emerging diagnostic technologiesForecasts sales of major tumor markers by country and market segmentProfiles leading market players and potential entrants Companies Mentioned: - Abbott - Beckman Coulter/Danaher - Becton Dickinson - Biomedical Diagnostics - bioMerieux - Bio-Rad - CellSearch - Cepheid - Correlogic Systems/Vermillion - Decode - Diadexus - Diagnocure - Enzo Biochem - Guided Therapeutics - Hologic/Gen-Probe - Kreatech - Kyowa Medex - Mackay Life Sciences - Myriad Genetics - PreMD - Qiagen/Ipsogen - Quest Diagnostics - Radient Pharmaceuticals - Roche - Sequenom - Siemens Healthcare - Takara Bio - Targeted Diagnostics & Therapeutics - Tosoh - Thermo Fisher/Life Technologies - Veridex - Wako Pure Chemicals - Wallac/PE - Zila For more information visit http://www.researchandmarkets.com/research/kj...strategies
MYGN: 34.32 (+0.82), DHR: 86.65 (+0.91), SQNM: 2.95 (+0.11), ENZ: 3.00 (+0.04), DGX: 71.58 (+0.74), CPHD: 58.15 (+0.75), HOLX: 38.71 (+0.75)
2015 Strategies in the US Point-of-Care/POC Coagulation Testing Market
M2 - Thu May 28, 9:56AM CDT
Research and Markets (http://www.researchandmarkets.com/research/x7wr4b/2015_strategies) has announced the addition of the "2015 Strategies in the US Point-of-Care/POC Coagulation Testing Market" report to their offering. This provides a comprehensive analysis of the POC coagulation testing market in the US, including trends, dynamics, size, growth, regulatory requirements, technological trends, competitive landscape, and emerging opportunities for instrument and consumable suppliers. This report will help diagnostic product suppliers develop effective business, R&D and marketing strategies for the global POC coagulation market. Companies Mentioned - Abbott - ADI/America Diagnostica - Agilent Technologies - Axis-Shield - Beckman Coulter/Danaher - Becton Dickinson - Bio/Data - Biomerieux - Bio-Rad - Biosite/Inverness/Alere - Cephid - Chrono-Log - Corgenix - Decode - Diadexus - Diagnocure - Diagnostica Stago/Trinity Biotech - Diamedix - Diasorin - Eiken Chemical - EKF Diagnostics - Fujirebio/Innogenetics - Helena Laboratories - Hologic/Gen-Probe - Horiba - Instrumentation Laboratory - International Technidyne/Nexus DX - Kreatech - Kyowa Medex - Life Technologies - Lonza - Mackay Life Sciences - Matritech - Nihon Kohden - Ortho-Clinical Diagnostics - Polartechnics - Polymedco - Qiagen - Roche - SDIX - Sequenom - Siemens - Sienco - Sysmex - Takara Bio - ThermoFisher - Tosoh - Wako - Zycare/Alere For more information visit http://www.researchandmarkets.com/research/x7...strategies
LIFE: 18.36 (+3.03), SQNM: 2.95 (+0.11), A: 39.40 (+0.48), DHR: 86.65 (+0.91), HOLX: 38.71 (+0.75)
Global Infectious Disease Molecular Diagnostics Market 2015: Country Forecasts, Supplier Shares, Emerging Technologies and Competitive Landscape
M2 - Mon May 18, 10:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q3j3fm/2015_global) has announced the addition of the "2015 Global Infectious Disease Molecular Diagnostics Market: Country Forecasts, Supplier Shares, Emerging Technologies and Competitive Landscape" report to their offering. This new seven-country study contains 1,265 pages, 191 tables, and is designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities in the infectious disease molecular diagnostics market during the next five years. The infectious disease molecular diagnostics market is one of the most rapidly growing segment of the in vitro diagnostics industry. The next five years will witness significant developments in reagent systems and automation, as well as introduction of a wide range of new products that will require innovative marketing approaches. The rate of market penetration into routine clinical laboratories, however, will depend on the introduction of cost-effective and automated systems with amplification methods. In order to successfully capitalize on the opportunities presented by the infectious disease molecular diagnostics market, many companies are already exploiting new molecular technologies as corporate strategic assets, managed in support of business and marketing strategies. Integrating new technology planning with business and corporate strategies will be one of the most challenging tasks for diagnostic companies during the next five years. Report Highlights - Business and technological trends in major markets - Five-year test volume and sales forecasts - Market shares of leading competitors - Feature comparison of major analyzers - Strategic profiles of leading market players and start-up firms developing innovative products - Specific product and business opportunities for instrument and consumable suppliers. Competitive Assessments - Abbott - Affymetrix - Agilent Technologies - Applied Gene Technologies - Arca Biopharma - Beckman Coulter/Danaher - Becton Dickinson - Biokit - bioMerieux - Bio-Rad - Biotest - Cepheid - CellMark Forenciscs/LabCorp - Decode Genetics - Diadexus - Eiken - Elitech Group - Enzo - Illumina - Kreatech - Li-Cor Biosciences - Monogram Biosciences/LabCorp - Myriad Genetics - Ortho-Clinical Diagnostics - Perkin Elmer/Caliper - Proteome Sciences - Qiagen - Roche - Shimadzu - Siemens - Sierra Molecular - Takara Bio - Tecan Group - Thermo Fisher For more information visit http://www.researchandmarkets.com/research/q3...015_global
MYGN: 34.32 (+0.82), A: 39.40 (+0.48), CPHD: 58.15 (+0.75), DHR: 86.65 (+0.91)
2015 Analysis of Molecular Diagnostic Instrumentation, and Strategic Profiles of Leading Suppliers
M2 - Mon May 18, 10:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fsnfz3/2015_analysis_of) has announced the addition of the "2015 Analysis of Molecular Diagnostic Instrumentation, and Strategic Profiles of Leading Suppliers" report to their offering. This 129-page report is designed to help suppliers identify and evaluate emerging opportunities for further automating molecular diagnostics methods in order to facilitate their penetration into the routine clinical laboratory market. Some instrumentation is already available on the market, e.g., DNA extractors, DNA synthesizers, thermal cyclers, robotic work-stations, and automated DNA probe analysis systems. The report reviews current instrumentation technologies, and compares features of leading molecular diagnostics analyzers marketed by Abbott, Beckman Coulter, BD, bioMerieux, Bio-Rad, Cepheid, Curetis, GenMark, Gen-Probe, HTG Molecular, Life Technologies, Qiagen, Roche, Siemens and Tecan. The report also presents strategic assessments of current and emerging suppliers of molecular diagnostic products, including their sales, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies. Companies Mentioned - Abbott - Affymetrix - Agilent Technologies - Applied Gene Technologies - Arca Biopharma - Beckman Coulter/Danaher - Becton Dickinson - Biokit - bioMerieux - Bio-Rad - CellMark Forenciscs/LabCorp - Decode Genetics - Diadexus - Eiken - Elitech Group - Enzo - Hologic/Gen-Probe - Illumina - Kreatech/Leica - Li-Cor Biosciences - Monogram Biosciences/LabCorp - Myriad Genetics - Ortho-Clinical Diagnostics - Perkin Elmer/Caliper - Proteome Sciences - Qiagen - Roche - Scienion - Sequenom - Siemens - Sierra Molecular - Takara Bio - Tecan Group - Thermo Fisher For more information visit http://www.researchandmarkets.com/research/fs...nalysis_of
SQNM: 2.95 (+0.11), MYGN: 34.32 (+0.82), A: 39.40 (+0.48), DHR: 86.65 (+0.91), HOLX: 38.71 (+0.75)
European Molecular Diagnostics Market 2015: Supplier Shares, Country Forecasts, Innovative Technologies, Competitive Strategies
M2 - Mon May 18, 10:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/l6qmwp/2015_european) has announced the addition of the "2015 European Molecular Diagnostics Market: Supplier Shares, Country Forecasts, Innovative Technologies, Competitive Strategies--Infectious Diseases, Genetic Diseases, Cancer, Forensic and Paternity Testing" report to their offering. This new 970-page comprehensive five-country report from a is designed to help current suppliers and potential market entrants identify and evaluate the major business opportunities emerging in the European molecular diagnostics market during the next five years. The report explores business and technological trends in major European countries (France, Germany, Italy, Spain, UK); provides 5-year test volume/sales forecasts; estimates shares of leading competitors; compares features of major analyzers; profiles leading market players; and identifies specific product and business opportunities facing instrument and consumable suppliers during the next five years. The $4.5 billion molecular diagnostics market is unquestionably the most rapidly growing segment of the in vitro diagnostics industry. The next five years will witness significant developments in reagent systems and automation, as well as introduction of a wide range of new products that will require innovative marketing approaches. The rate of market penetration into routine clinical laboratories, however, will depend on the introduction of and cost-effective automated systems with amplification methods. In order to successfully capitalize on the opportunities presented by the molecular diagnostics market, many companies are already exploiting new technologies as corporate strategic assets, managed in support of business and marketing strategies. Integrating new technology planning with business and corporate strategies will be one of the most challenging tasks for diagnostics companies during the next five years. Key Topics Covered: I. Introduction II. Worldwide Technology and Market Overview III. France IV. Germany V. Italy VI. Spain VII. U.K. VIII. Major Product Development Opportunities IX. Design Criteria for Decentralized Testing Products X. Alternative Market Penetration Strategies XI. Potential Market Entry Barriers and Risks XII. Competitive Assessments XIII. Appendix Companies Mentioned - Abbott - Affymetrix - Agilent - Applied Gene Technologies - Arca - Beckman Coulter/Danaher - Becton Dickinson - Biokit - BioMerieux - Bio-Rad - Caliper - Cepheid - Decode - Diadexus - Eiken - Enzo - Exact Sciences - Innogenetics/Solvay - Kreatech - Li-Cor Biosciences - Life Technologies - Monogram Biosciences - Myriad Genetics - Nanogen/Elitech - Novartis - Orchid CellMark - Ortho-Clinical Diagnostics - Proteome Sciences - Qiagen - Roche - Scienion - Sequenom - Shimadzu - Siemens - Tecan Group For more information visit http://www.researchandmarkets.com/research/l6...5_european
LIFE: 18.36 (+3.03), MYGN: 34.32 (+0.82), DHR: 86.65 (+0.91), SQNM: 2.95 (+0.11), CPHD: 58.15 (+0.75), NVS: 103.22 (+3.20)
United States Molecular Diagnostics Market 2015: Supplier Shares, Country Forecasts, Innovative Technologies, Competitive Strategies
M2 - Mon May 18, 9:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7jn7rn/2015_us_molecular) has announced the addition of the "2015 US Molecular Diagnostics Market: Supplier Shares, Country Forecasts, Innovative Technologies, Competitive Strategies--Infectious Diseases, Genetic Diseases, Cancer, Forensic and Paternity Testing" report to their offering. This new 1157-page report from a contains 37 tables, and presents a comprehensive analysis of the US molecular diagnostics market, including: Major issues pertaining to the US molecular diagnostics laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next five years.An extensive review of DNA probe and biochip technologies, test formats, detection methodologies, trends in testing automation and amplification methods. Review of testing methodologies an instrumentation technologies.Feature comparison of automated and semiautomated analyzers.Sales and market shares of leading suppliers.Over 60 specific opportunities for molecular diagnostic instruments, test systems, IT and auxiliary products.Profiles of major suppliers, and emerging market entrants, including their sales, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies. Alternative market penetration strategies. Potential market entry barriers and risks. Business planning issues and concerns. Five-year test volume and reagent sales forecasts for the following categories: - Infectious Diseases -Genetic Diseases - Cancer - Paternity Testing/HLA Typing - Forensic Testing Key Topics Covered: I. Introduction II. Major Product Development Opportunities III. Design Criteria for Decentralized Testing Products IV. Alternative Market Penetration Strategies V. Potential Market Entry Barriers and Risks VI. Worldwide Market and Technology Review VII. US Molecular Diagnostics Market VIII. Competitive Assessments - Abbott - Affymetrix - Agilent Technologies - Applied Gene Technologies - Arca Biopharma - Beckman Coulter/Danaher - Becton Dickinson - Biokit - bioMerieux - Bio-Rad - Biotest - Cepheid - CellMark Forenciscs/LabCorp - Decode Genetics - Diadexus - Eiken - Elitech Group - Enzo - Exact Sciences - Fujirebio - Grifols - Hologic/Gen-Probe - Illumina - Kreatech - Li-Cor Biosciences - Monogram Biosciences/LabCorp - Myriad Genetics - Ortho-Clinical Diagnostics - Perkin Elmer/Caliper - Shimadzu - Siemens - Sierra Molecular - Takara Bio - Tecan Group - Thermo Fisher For more information visit http://www.researchandmarkets.com/research/7j..._molecular
MYGN: 34.32 (+0.82), A: 39.40 (+0.48), CPHD: 58.15 (+0.75), DHR: 86.65 (+0.91), HOLX: 38.71 (+0.75)
Diadexus, Inc. Reports First Quarter 2015 Financial Results
Marketwired - Tue May 12, 3:00PM CDT
Diadexus, Inc. (OTCQB: DDXS), a diagnostics company developing and commercializing products that aid in the prediction of cardiac disease risk, today announced financial results for the first quarter ended March 31, 2015 and provided an update on the business.
Diadexus, Inc. to Report First Quarter 2015 Financial Results on May 12, 2015
Marketwired - Tue May 05, 3:05PM CDT
Diadexus, Inc. (OTCQB: DDXS), a diagnostics company developing and commercializing products that aid in the prediction of cardiac disease risk, today announced that it will report first quarter 2015 financial results on Tuesday, May 12, 2015 after market close, and will host a conference call to discuss financial results and provide a business update at 4:30 p.m. ET (1:30 p.m. PT).
Lori Rafield, Ph.D. Appointed Permanent CEO of Diadexus
Marketwired - Mon Apr 20, 8:30AM CDT
Diadexus, Inc. (OTCQB: DDXS), a diagnostics company developing and commercializing products that aid in the prediction of cardiac disease risk, today announced the appointment of Lori F. Rafield, Ph.D. as chief executive officer of the Company on a permanent basis, effective immediately. Dr. Rafield has continued to serve as chairman since 2010. She assumed the responsibility of interim executive chair in June 2014 and then was appointed interim chief executive officer in January 2015.
Diadexus, Inc. Announces Presentation of Results From the PLAC(R) Activity Test Clinical Validation Study
Marketwired - Tue Mar 24, 1:00PM CDT
Diadexus, Inc. (OTCQB: DDXS), a diagnostics company developing and commercializing products that aid in the prediction of cardiac disease risk, today announced results from the PLAC(R) Test for Lp-PLA2 Activity (PLAC(R) Activity Test) clinical validation study, presented for the first time today during an oral presentation at the European Atherosclerosis Society 83rd Congress in Glasgow, UK. The results from this study were used in the 510(k) submission for this new test, which was cleared by the U.S. Food and Drug Administration in December 2014 for use in conjunction with clinical evaluation and patient risk assessment as an aid in predicting risk of coronary heart disease (CHD) in patients with no prior history of cardiovascular events.
diaDexus misses by $0.01, misses on revenue
Seeking Alpha - at Seeking Alpha - Wed Mar 11, 3:28PM CDT
Diadexus, Inc. Reports Fourth Quarter and Full Year 2014 Financial Results
Marketwired - Wed Mar 11, 3:00PM CDT
Diadexus, Inc. (OTCQB: DDXS), a diagnostics company developing and commercializing products that aid in the prediction of cardiac disease risk, today announced financial results for the fourth quarter and full year ended December 31, 2014.
Diadexus, Inc. Names William Hammond as Vice President of Sales
Marketwired - Tue Jul 07, 8:15AM CDT
Diadexus, Inc. (OTCQB: DDXS), a diagnostics company developing and commercializing products that aid in the prediction of cardiac disease risk, today announced that William Harrison Hammond (Hodi) has joined the Company as Vice President of Sales effective June 22, 2015. Mr. Hammond brings more than 30 years of experience in the medical diagnostics field, including 13 years in various senior and executive roles at Alere and 11 years at Abbott Diagnostics.
Diadexus approves one for 15 reverse stock split
M2 - Thu Jul 02, 6:49AM CDT
Diagnostics company Diadexus (OTCQB
DXS) reported on Wednesday the completion of a one for-15 reverse stock split of its common stock on 30 June 2015. Diadexus 1:15 reverse split shares trade today
Seeking Alpha - at Seeking Alpha - Wed Jul 01, 9:33AM CDT
Diadexus, Inc. Announces Reverse Stock Split
Marketwired - Wed Jul 01, 8:15AM CDT
Diadexus, Inc. (OTCQB: DDXS), a diagnostics company developing and commercializing products that aid in the prediction of cardiac disease risk, today announced that it has completed a 1-for-15 reverse stock split of its common stock, effective as of 5:00 pm Eastern Time June 30, 2015. Beginning with the opening of trading today the Company's common stock will trade on OTCQB on a post-split basis.
2015 UK Infectious Disease Molecular Diagnostics Market: Country Forecasts, Supplier Shares, Emerging Technologies and Competitive Landscape
M2 - Wed Jun 24, 6:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9b6wsz/2015_uk) has announced the addition of the "2015 UK Infectious Disease Molecular Diagnostics Market: Country Forecasts, Supplier Shares, Emerging Technologies and Competitive Landscape" report to their offering. This new study contains 977 pages, 50 tables, and is designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities in the infectious disease molecular diagnostics market during the next five years. In order to successfully capitalize on the opportunities presented by the infectious disease molecular diagnostics market, many companies are already exploiting new molecular technologies as corporate strategic assets, managed in support of business and marketing strategies. Integrating new technology planning with business and corporate strategies will be one of the most challenging tasks for diagnostic companies during the next five years. Report Highlights - Business and technological trends in major markets - Five-year test volume and sales forecasts - Market shares of leading competitors - Feature comparison of major analyzers - Strategic profiles of leading market players and start-up firms developing innovative products - Specific product and business opportunities for instrument and consumable suppliers. U.K. Market Overview - Laboratories performing DNA sequencing and molecular diagnostic testing for infectious diseases and market segment. - Five-year test volume and sales projections. Market Segmentation Analysis - Sales and market shares of leading suppliers of infectious disease molecular diagnostic reagent kits and components. - Five-year test volume and sales projections for over 40 infectious disease molecular diagnostic assays. - A comprehensive analysis of the sequencing market and laboratory segment. - Detailed market segmentation analysis, including review of the market dynamics, trends, structure, size, growth and major suppliers. Product/Technology Review - Comparison of leading infectious disease molecular diagnostic analyzers. - Extensive review of molecular diagnostic technologies, test formats, detection methodologies, trends in testing automation and over target/signal amplification methods. - Worldwide listings of companies, universities and research centers developing new molecular diagnostic technologies and products. Competitive Assessments - Abbott - Affymetrix - Agilent Technologies - Applied Gene Technologies - Arca Biopharma - Beckman Coulter/Danaher - Becton Dickinson - Biokit - bioMerieux - Bio-Rad - Biotest - Cepheid - CellMark Forenciscs/LabCorp - Decode Genetics - Diadexus - Hologic/Gen-Probe - Illumina - Kreatech - Li-Cor Biosciences - Monogram Biosciences/LabCorp - Myriad Genetics - Ortho-Clinical Diagnostics - Perkin Elmer/Caliper - Proteome Sciences - Qiagen - Roche - Scienion - Sequenom - Shimadzu - Siemens - Sierra Molecular - Takara Bio - Tecan Group - Thermo Fisher For more information visit http://www.researchandmarkets.com/research/9b6wsz/2015_uk
SQNM: 2.95 (+0.11), MYGN: 34.32 (+0.82), A: 39.40 (+0.48), CPHD: 58.15 (+0.75), DHR: 86.65 (+0.91), HOLX: 38.71 (+0.75)
2015 Cancer Diagnostics: A Market on the Verge of Explosion--Technological Breakthroughs, Emerging Tests, Market Forecasts, Competitive Intelligence
M2 - Thu Jun 18, 12:14PM CDT
Research and Markets (http://www.researchandmarkets.com/research/x472n5/2015_cancer) has announced the addition of the "2015 Cancer Diagnostics: A Market on the Verge of Explosion--Technological Breakthroughs, Emerging Tests, Market Forecasts, Competitive Intelligence" report to their offering. The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease.During the next five years, the worldwide cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field.Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy.The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide. Geographic Coverage France, Germany, Italy, Japan, Spain, UK, USA - The companies analyzed in the report include - Abbott - AdnaGen - Agilent Technologies - Applied Gene Technologies - Arca Pharma - Beckman Coulter/Danaher - Becton Dickinson - Biomedical Diagnostics - bioMerieux - Bio-Rad - CellSearch - Cepheid - Correlogic Systems/Vermillion - Decode Genetics - Diadexus - Diagnocure - Diasorin - Eiken Chemical - Elitech Group - Epigenomics - Enterix - Enzo Biochem - Exact Sciences - Fujirebio - Guided Therapeutics - Hologic/Gen-Probe - Kreatech/Leica - Kyowa Medex - Mackay Life Sciences - Myriad Genetics - OncoLab - Ortho-Clinical Diagnostics - Panacea Pharmaceuticals - Polartechnics - Polymedco - PreMD - Qiagen/Ipsogen - Quest Diagnostics - Radient Pharmaceuticals - Roche - Scienion - Sequenom - Siemens Healthcare - Takara Bio - Targeted Diagnostics & Therapeutics - Thermo Fisher - Tosoh - Veridex - Wako Pure Chemicals - Wallac/PE - Zila For more information visit http://www.researchandmarkets.com/research/x4...015_cancer About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
MYGN: 34.32 (+0.82), A: 39.40 (+0.48), DHR: 86.65 (+0.91), SQNM: 2.95 (+0.11), ENZ: 3.00 (+0.04), DGX: 71.58 (+0.74), CPHD: 58.15 (+0.75), HOLX: 38.71 (+0.75)
2015 New Frontiers in the Italian Cancer Diagnostics Market: Business Challenges, Emerging Technologies, Competitive Landscape (Datapack)
M2 - Wed Jun 10, 9:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/t5ptkf/2015_new) has announced the addition of the "2015 New Frontiers in the Italian Cancer Diagnostics Market: Business Challenges, Emerging Technologies, Competitive Landscape (Datapack)" report to their offering. This is a new study of the major business opportunities emerging in the Italian cancer diagnostics market during the next five years. The report examines trends in the Italian cancer diagnostics markets, reviews current and emerging assays; analyzes potential applications of new diagnostic technologies; forecasts sales of major tumor markers by market segment; profiles leading players and potential market entrants; and identifies specific business opportunities for suppliers. Italian Market Overview: - Five-year test volume and sales projections. - Comprehensive market segmentation analysis, including review of the market dynamics, structure, size, growth and major suppliers. - Estimated universe of laboratories performing cancer diagnostic testing. - Cancer statistics, etiology and recent developments. Business Opportunities and Strategic Recommendations: - Specific new product development opportunities with potentially significant market appeal during the next five years. - Design criteria for new products. - Alternative market penetration strategies. - Potential market entry barriers and risks. Over 200 Current and Emerging Cancer Diagnostic Test: - Biochemical Markers - Oncogenes - Growth Factors - Hormones - Colony Stimulating Factors - Lymphokines - Immunohistochemical Stains, and others. Supplier Shares, Sales and Volume Forecasts: - Sales and market shares of major cancer diagnostic product suppliers by individual test. - Five-year test volume and sales forecasts for major tumor markers by market segment, including: - Hospitals - Commercial/Private Laboratories Instrumentation Review: - Analysis of major molecular diagnostic and immunodignostic analyzers used for cancer testing, including their operating characteristics, features and selling prices. Technology Assessment: - Assessment of latest molecular diagnostic methods, biochips/microarrays, biosensors, monoclonal antibodies, immunoassays, chromosome analysis, IT, artificial intelligence, flow cytometry, and other technologies and their potential applications for cancer diagnostic testing. - Review of competing/complementing technologies, including CT, MRI, NMR, PET and photonics spectroscopy. - Extensive listings of companies, universities and research centers developing new cancer diagnostic tests and detection technologies. Competitive Strategies: - Strategic assessments of major suppliers and start-up firms developing innovative technologies and products, including their sales, product portfolios, marketing tactics, collaborative arrangements, and new products in R&D. Companies Mentioned - Abbott - AdnaGen/Alere - Agilent Technologies - Applied Gene Technologies - Arca Pharma - Bckman Coulter/Danaher - Becton Dickinson - Biomedical Diagnostics - bioMerieux - Bio-Rad - CellSearch - Cepheid - Correlogic Systems/Vermillion - Decode Genetics - Diadexus - Diagnocure - Enzo Biochem - Exact Sciences - Fujirebio - Guided Therapeutics - Hologic/Gen-Probe - Kreatech/Leica - Kyowa Medex - Mackay Life Sciences - Polymedco - PreMD - Qiagen - Quest Diagnostics - Radient Pharmaceuticals - Roche - Scienion - Sequenom - Wako Pure Chemicals - Wallac/PE - Zilla For more information visit http://www.researchandmarkets.com/research/t5ptkf/2015_new
SQNM: 2.95 (+0.11), ENZ: 3.00 (+0.04), A: 39.40 (+0.48), DGX: 71.58 (+0.74), CPHD: 58.15 (+0.75), HOLX: 38.71 (+0.75)
2015 Strategies in the US Physician Office and Group Practice Diagnostic Testing Market
M2 - Wed Jun 03, 10:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mqms5f/2015_strategies) has announced the addition of the "2015 Strategies in the US Physician Office and Group Practice Diagnostic Testing Market" report to their offering. This new 970-page report contains 152 tables and provides comprehensive analysis of the physician office/group practice diagnostics market, including its dynamics, size, growth, regulatory requirements, technological trends, competitive landscape, and emerging opportunities for instrument and consumable suppliers. Companies Mentioned: - Abbott - ADI/America Diagnostica - Agilent Technologies - Axis-Shield - Beckman Coulter/Danaher - Becton Dickinson - Bio/Data - Biomerieux - Bio-Rad - Biosite/Inverness/Alere - Cepheid - Chrono-Log - Corgenix - Decode - Diadexus - Diagnocure - Diagnostica Stago/Trinity Biotech - Diamedix - Diasorin - Eiken Chemical - EKF Diagnostics - Fujirebio/Innogenetics - Helena Laboratories - Hologic/Gen-Probe - Horiba - Instrumentation Laboratory - International Technidyne/Nexus DX - Kreatech - Kyowa Medex - Life Technologies - Lonza - Polymedco - Qiagen - Roche - SDIX For more information visit http://www.researchandmarkets.com/research/mq...strategies
LIFE: 18.36 (+3.03), A: 39.40 (+0.48), CPHD: 58.15 (+0.75), DHR: 86.65 (+0.91), HOLX: 38.71 (+0.75)
2015 Strategies in the Global Tumor Marker Testing Market
M2 - Fri May 29, 5:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kj6pzz/2015_strategies) has announced the addition of the "2015 Strategies in the Global Tumor Marker Testing Market: US, Europe, Japan" report to their offering. Identifies and evaluates major business opportunities emerging in the tumor marker market during the next five yearsExamines trends in the U.S., Europe and JapanReviews current and emerging tumor markersAnalyzes applications of emerging diagnostic technologiesForecasts sales of major tumor markers by country and market segmentProfiles leading market players and potential entrants Companies Mentioned: - Abbott - Beckman Coulter/Danaher - Becton Dickinson - Biomedical Diagnostics - bioMerieux - Bio-Rad - CellSearch - Cepheid - Correlogic Systems/Vermillion - Decode - Diadexus - Diagnocure - Enzo Biochem - Guided Therapeutics - Hologic/Gen-Probe - Kreatech - Kyowa Medex - Mackay Life Sciences - Myriad Genetics - PreMD - Qiagen/Ipsogen - Quest Diagnostics - Radient Pharmaceuticals - Roche - Sequenom - Siemens Healthcare - Takara Bio - Targeted Diagnostics & Therapeutics - Tosoh - Thermo Fisher/Life Technologies - Veridex - Wako Pure Chemicals - Wallac/PE - Zila For more information visit http://www.researchandmarkets.com/research/kj...strategies
MYGN: 34.32 (+0.82), DHR: 86.65 (+0.91), SQNM: 2.95 (+0.11), ENZ: 3.00 (+0.04), DGX: 71.58 (+0.74), CPHD: 58.15 (+0.75), HOLX: 38.71 (+0.75)
2015 Strategies in the US Point-of-Care/POC Coagulation Testing Market
M2 - Thu May 28, 9:56AM CDT
Research and Markets (http://www.researchandmarkets.com/research/x7wr4b/2015_strategies) has announced the addition of the "2015 Strategies in the US Point-of-Care/POC Coagulation Testing Market" report to their offering. This provides a comprehensive analysis of the POC coagulation testing market in the US, including trends, dynamics, size, growth, regulatory requirements, technological trends, competitive landscape, and emerging opportunities for instrument and consumable suppliers. This report will help diagnostic product suppliers develop effective business, R&D and marketing strategies for the global POC coagulation market. Companies Mentioned - Abbott - ADI/America Diagnostica - Agilent Technologies - Axis-Shield - Beckman Coulter/Danaher - Becton Dickinson - Bio/Data - Biomerieux - Bio-Rad - Biosite/Inverness/Alere - Cephid - Chrono-Log - Corgenix - Decode - Diadexus - Diagnocure - Diagnostica Stago/Trinity Biotech - Diamedix - Diasorin - Eiken Chemical - EKF Diagnostics - Fujirebio/Innogenetics - Helena Laboratories - Hologic/Gen-Probe - Horiba - Instrumentation Laboratory - International Technidyne/Nexus DX - Kreatech - Kyowa Medex - Life Technologies - Lonza - Mackay Life Sciences - Matritech - Nihon Kohden - Ortho-Clinical Diagnostics - Polartechnics - Polymedco - Qiagen - Roche - SDIX - Sequenom - Siemens - Sienco - Sysmex - Takara Bio - ThermoFisher - Tosoh - Wako - Zycare/Alere For more information visit http://www.researchandmarkets.com/research/x7...strategies
LIFE: 18.36 (+3.03), SQNM: 2.95 (+0.11), A: 39.40 (+0.48), DHR: 86.65 (+0.91), HOLX: 38.71 (+0.75)
Global Infectious Disease Molecular Diagnostics Market 2015: Country Forecasts, Supplier Shares, Emerging Technologies and Competitive Landscape
M2 - Mon May 18, 10:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q3j3fm/2015_global) has announced the addition of the "2015 Global Infectious Disease Molecular Diagnostics Market: Country Forecasts, Supplier Shares, Emerging Technologies and Competitive Landscape" report to their offering. This new seven-country study contains 1,265 pages, 191 tables, and is designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities in the infectious disease molecular diagnostics market during the next five years. The infectious disease molecular diagnostics market is one of the most rapidly growing segment of the in vitro diagnostics industry. The next five years will witness significant developments in reagent systems and automation, as well as introduction of a wide range of new products that will require innovative marketing approaches. The rate of market penetration into routine clinical laboratories, however, will depend on the introduction of cost-effective and automated systems with amplification methods. In order to successfully capitalize on the opportunities presented by the infectious disease molecular diagnostics market, many companies are already exploiting new molecular technologies as corporate strategic assets, managed in support of business and marketing strategies. Integrating new technology planning with business and corporate strategies will be one of the most challenging tasks for diagnostic companies during the next five years. Report Highlights - Business and technological trends in major markets - Five-year test volume and sales forecasts - Market shares of leading competitors - Feature comparison of major analyzers - Strategic profiles of leading market players and start-up firms developing innovative products - Specific product and business opportunities for instrument and consumable suppliers. Competitive Assessments - Abbott - Affymetrix - Agilent Technologies - Applied Gene Technologies - Arca Biopharma - Beckman Coulter/Danaher - Becton Dickinson - Biokit - bioMerieux - Bio-Rad - Biotest - Cepheid - CellMark Forenciscs/LabCorp - Decode Genetics - Diadexus - Eiken - Elitech Group - Enzo - Illumina - Kreatech - Li-Cor Biosciences - Monogram Biosciences/LabCorp - Myriad Genetics - Ortho-Clinical Diagnostics - Perkin Elmer/Caliper - Proteome Sciences - Qiagen - Roche - Shimadzu - Siemens - Sierra Molecular - Takara Bio - Tecan Group - Thermo Fisher For more information visit http://www.researchandmarkets.com/research/q3...015_global
MYGN: 34.32 (+0.82), A: 39.40 (+0.48), CPHD: 58.15 (+0.75), DHR: 86.65 (+0.91)
2015 Analysis of Molecular Diagnostic Instrumentation, and Strategic Profiles of Leading Suppliers
M2 - Mon May 18, 10:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fsnfz3/2015_analysis_of) has announced the addition of the "2015 Analysis of Molecular Diagnostic Instrumentation, and Strategic Profiles of Leading Suppliers" report to their offering. This 129-page report is designed to help suppliers identify and evaluate emerging opportunities for further automating molecular diagnostics methods in order to facilitate their penetration into the routine clinical laboratory market. Some instrumentation is already available on the market, e.g., DNA extractors, DNA synthesizers, thermal cyclers, robotic work-stations, and automated DNA probe analysis systems. The report reviews current instrumentation technologies, and compares features of leading molecular diagnostics analyzers marketed by Abbott, Beckman Coulter, BD, bioMerieux, Bio-Rad, Cepheid, Curetis, GenMark, Gen-Probe, HTG Molecular, Life Technologies, Qiagen, Roche, Siemens and Tecan. The report also presents strategic assessments of current and emerging suppliers of molecular diagnostic products, including their sales, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies. Companies Mentioned - Abbott - Affymetrix - Agilent Technologies - Applied Gene Technologies - Arca Biopharma - Beckman Coulter/Danaher - Becton Dickinson - Biokit - bioMerieux - Bio-Rad - CellMark Forenciscs/LabCorp - Decode Genetics - Diadexus - Eiken - Elitech Group - Enzo - Hologic/Gen-Probe - Illumina - Kreatech/Leica - Li-Cor Biosciences - Monogram Biosciences/LabCorp - Myriad Genetics - Ortho-Clinical Diagnostics - Perkin Elmer/Caliper - Proteome Sciences - Qiagen - Roche - Scienion - Sequenom - Siemens - Sierra Molecular - Takara Bio - Tecan Group - Thermo Fisher For more information visit http://www.researchandmarkets.com/research/fs...nalysis_of
SQNM: 2.95 (+0.11), MYGN: 34.32 (+0.82), A: 39.40 (+0.48), DHR: 86.65 (+0.91), HOLX: 38.71 (+0.75)
European Molecular Diagnostics Market 2015: Supplier Shares, Country Forecasts, Innovative Technologies, Competitive Strategies
M2 - Mon May 18, 10:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/l6qmwp/2015_european) has announced the addition of the "2015 European Molecular Diagnostics Market: Supplier Shares, Country Forecasts, Innovative Technologies, Competitive Strategies--Infectious Diseases, Genetic Diseases, Cancer, Forensic and Paternity Testing" report to their offering. This new 970-page comprehensive five-country report from a is designed to help current suppliers and potential market entrants identify and evaluate the major business opportunities emerging in the European molecular diagnostics market during the next five years. The report explores business and technological trends in major European countries (France, Germany, Italy, Spain, UK); provides 5-year test volume/sales forecasts; estimates shares of leading competitors; compares features of major analyzers; profiles leading market players; and identifies specific product and business opportunities facing instrument and consumable suppliers during the next five years. The $4.5 billion molecular diagnostics market is unquestionably the most rapidly growing segment of the in vitro diagnostics industry. The next five years will witness significant developments in reagent systems and automation, as well as introduction of a wide range of new products that will require innovative marketing approaches. The rate of market penetration into routine clinical laboratories, however, will depend on the introduction of and cost-effective automated systems with amplification methods. In order to successfully capitalize on the opportunities presented by the molecular diagnostics market, many companies are already exploiting new technologies as corporate strategic assets, managed in support of business and marketing strategies. Integrating new technology planning with business and corporate strategies will be one of the most challenging tasks for diagnostics companies during the next five years. Key Topics Covered: I. Introduction II. Worldwide Technology and Market Overview III. France IV. Germany V. Italy VI. Spain VII. U.K. VIII. Major Product Development Opportunities IX. Design Criteria for Decentralized Testing Products X. Alternative Market Penetration Strategies XI. Potential Market Entry Barriers and Risks XII. Competitive Assessments XIII. Appendix Companies Mentioned - Abbott - Affymetrix - Agilent - Applied Gene Technologies - Arca - Beckman Coulter/Danaher - Becton Dickinson - Biokit - BioMerieux - Bio-Rad - Caliper - Cepheid - Decode - Diadexus - Eiken - Enzo - Exact Sciences - Innogenetics/Solvay - Kreatech - Li-Cor Biosciences - Life Technologies - Monogram Biosciences - Myriad Genetics - Nanogen/Elitech - Novartis - Orchid CellMark - Ortho-Clinical Diagnostics - Proteome Sciences - Qiagen - Roche - Scienion - Sequenom - Shimadzu - Siemens - Tecan Group For more information visit http://www.researchandmarkets.com/research/l6...5_european
LIFE: 18.36 (+3.03), MYGN: 34.32 (+0.82), DHR: 86.65 (+0.91), SQNM: 2.95 (+0.11), CPHD: 58.15 (+0.75), NVS: 103.22 (+3.20)
United States Molecular Diagnostics Market 2015: Supplier Shares, Country Forecasts, Innovative Technologies, Competitive Strategies
M2 - Mon May 18, 9:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7jn7rn/2015_us_molecular) has announced the addition of the "2015 US Molecular Diagnostics Market: Supplier Shares, Country Forecasts, Innovative Technologies, Competitive Strategies--Infectious Diseases, Genetic Diseases, Cancer, Forensic and Paternity Testing" report to their offering. This new 1157-page report from a contains 37 tables, and presents a comprehensive analysis of the US molecular diagnostics market, including: Major issues pertaining to the US molecular diagnostics laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next five years.An extensive review of DNA probe and biochip technologies, test formats, detection methodologies, trends in testing automation and amplification methods. Review of testing methodologies an instrumentation technologies.Feature comparison of automated and semiautomated analyzers.Sales and market shares of leading suppliers.Over 60 specific opportunities for molecular diagnostic instruments, test systems, IT and auxiliary products.Profiles of major suppliers, and emerging market entrants, including their sales, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies. Alternative market penetration strategies. Potential market entry barriers and risks. Business planning issues and concerns. Five-year test volume and reagent sales forecasts for the following categories: - Infectious Diseases -Genetic Diseases - Cancer - Paternity Testing/HLA Typing - Forensic Testing Key Topics Covered: I. Introduction II. Major Product Development Opportunities III. Design Criteria for Decentralized Testing Products IV. Alternative Market Penetration Strategies V. Potential Market Entry Barriers and Risks VI. Worldwide Market and Technology Review VII. US Molecular Diagnostics Market VIII. Competitive Assessments - Abbott - Affymetrix - Agilent Technologies - Applied Gene Technologies - Arca Biopharma - Beckman Coulter/Danaher - Becton Dickinson - Biokit - bioMerieux - Bio-Rad - Biotest - Cepheid - CellMark Forenciscs/LabCorp - Decode Genetics - Diadexus - Eiken - Elitech Group - Enzo - Exact Sciences - Fujirebio - Grifols - Hologic/Gen-Probe - Illumina - Kreatech - Li-Cor Biosciences - Monogram Biosciences/LabCorp - Myriad Genetics - Ortho-Clinical Diagnostics - Perkin Elmer/Caliper - Shimadzu - Siemens - Sierra Molecular - Takara Bio - Tecan Group - Thermo Fisher For more information visit http://www.researchandmarkets.com/research/7j..._molecular
MYGN: 34.32 (+0.82), A: 39.40 (+0.48), CPHD: 58.15 (+0.75), DHR: 86.65 (+0.91), HOLX: 38.71 (+0.75)
Diadexus, Inc. Reports First Quarter 2015 Financial Results
Marketwired - Tue May 12, 3:00PM CDT
Diadexus, Inc. (OTCQB: DDXS), a diagnostics company developing and commercializing products that aid in the prediction of cardiac disease risk, today announced financial results for the first quarter ended March 31, 2015 and provided an update on the business.
Diadexus, Inc. to Report First Quarter 2015 Financial Results on May 12, 2015
Marketwired - Tue May 05, 3:05PM CDT
Diadexus, Inc. (OTCQB: DDXS), a diagnostics company developing and commercializing products that aid in the prediction of cardiac disease risk, today announced that it will report first quarter 2015 financial results on Tuesday, May 12, 2015 after market close, and will host a conference call to discuss financial results and provide a business update at 4:30 p.m. ET (1:30 p.m. PT).
Lori Rafield, Ph.D. Appointed Permanent CEO of Diadexus
Marketwired - Mon Apr 20, 8:30AM CDT
Diadexus, Inc. (OTCQB: DDXS), a diagnostics company developing and commercializing products that aid in the prediction of cardiac disease risk, today announced the appointment of Lori F. Rafield, Ph.D. as chief executive officer of the Company on a permanent basis, effective immediately. Dr. Rafield has continued to serve as chairman since 2010. She assumed the responsibility of interim executive chair in June 2014 and then was appointed interim chief executive officer in January 2015.
Diadexus, Inc. Announces Presentation of Results From the PLAC(R) Activity Test Clinical Validation Study
Marketwired - Tue Mar 24, 1:00PM CDT
Diadexus, Inc. (OTCQB: DDXS), a diagnostics company developing and commercializing products that aid in the prediction of cardiac disease risk, today announced results from the PLAC(R) Test for Lp-PLA2 Activity (PLAC(R) Activity Test) clinical validation study, presented for the first time today during an oral presentation at the European Atherosclerosis Society 83rd Congress in Glasgow, UK. The results from this study were used in the 510(k) submission for this new test, which was cleared by the U.S. Food and Drug Administration in December 2014 for use in conjunction with clinical evaluation and patient risk assessment as an aid in predicting risk of coronary heart disease (CHD) in patients with no prior history of cardiovascular events.
diaDexus misses by $0.01, misses on revenue
Seeking Alpha - at Seeking Alpha - Wed Mar 11, 3:28PM CDT
Diadexus, Inc. Reports Fourth Quarter and Full Year 2014 Financial Results
Marketwired - Wed Mar 11, 3:00PM CDT
Diadexus, Inc. (OTCQB: DDXS), a diagnostics company developing and commercializing products that aid in the prediction of cardiac disease risk, today announced financial results for the fourth quarter and full year ended December 31, 2014.
